State restrictions
State Bills Banning Medical Treatment for Transgender Youth: The Effect on Families
Do these bans protect child welfare, or preserve traditional views of biological sex? Families are caught in the middle either way. [†]
Starting January 2021, states began proposing bans on puberty blockers, hormone therapy, and gender-related surgery for minors. (Puberty blockers — gonadotropin-releasing hormone agonists — have been used since the 1980s to delay early puberty; synthetic hormones were first used for intersex children in the 1930s, then transgender youth shortly after.) By April 2022, 20 states had proposed such laws, with three enacted (Alabama, Arkansas, Tennessee); restrictions vary by age and treatment type, generally exclude youth with chromosomal or sexual development conditions, and can carry felony or civil liability for providers.
The child-protection framing: these bills are cast as protecting children from medical procedures without adequate scientific support, encouraging mental health treatment first given pre-existing psychiatric conditions. Arkansas's bill, for instance, noted the absence of randomized controlled trials on cross-sex hormones for this purpose — though one such trial is now underway. Georgia's proposed "Vulnerable Child Protection Act" and Texas's classification of these treatments as child abuse follow similar logic; in February 2022, Texas's governor directed state investigations into families pursuing this care, though a state judge later ruled the policy improperly adopted and temporarily halted it.
The counter-framing: these bills may instead function to preserve a traditional link between gender and biological sex, since child-protection laws normally presume parental neglect or abuse — yet parental consent is already required for these treatments. This raises the question of why the state would override parental medical decisions here specifically, but not elsewhere. Proponents' concerns about insufficient evidence also cut both ways: about half of all medical treatments generally lack strong evidence, and off-label prescribing affects roughly 21% of medications overall — raising the question of why this particular, relatively small population draws such intense scrutiny.
How restrictions compare to existing guidelines: in practice, the bans may change little, since current guidelines already don't recommend gender-related surgery under 18 or hormone therapy before puberty begins. Arkansas's surgery ban and Tennessee's prepubertal hormone ban both track existing practice rather than changing it — meaning the main effect may fall on families rather than on clinical practice itself.
Effects on families, regardless of one's view of the underlying treatments:[†]
-
Parents may fear for their child's emotional and physical safety — including clergy members themselves navigating this with their own children
-
Family conflict between the transgender member and others may increase
-
Youth who feel alienated may face higher anxiety, depression, suicide risk, or substance use, and may come to mistrust the health care system broadly, affecting unrelated future care
-
Non-transgender family members may feel stigma, helplessness, or a sense of being abandoned by the health and government systems
-
Some families consider relocating to states without restrictions — which can isolate them from existing support networks
-
Restricted access to monitored hormone therapy may push some toward unsupervised, unmonitored alternatives
Notably, psychotherapy itself isn't restricted by these laws, meaning demand for psychotherapeutic support (for gender dysphoria as well as related depression, anxiety, and substance use) may rise even as medical options narrow. Social transition, without medical intervention, also remains available to families in restricted states.
[†] This section describes documented effects on families regardless of a reader's own view of whether these laws are appropriate — it is not making an argument for or against the legislation itself.
Continue exploring: